pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Anaxis Pharma clinical programs — 223 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
Anaxis Pharma projects
223 ClinicalTrials.gov programs sponsored by Anaxis Pharma.
Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
SynAct-CS010
Lacuna Pharma Pty Ltd
Polymyalgia rheumatica
1 trial -
TAR-0520 Gel
Lacuna Pharma Pty Ltd
Capecitabine-induced hand and foot syndrome
1 trial -
TAR-0520 Gel
Lacuna Pharma Pty Ltd
Taxanes-induced peripheral neuropathy
1 trial -
TARIAN 007
Lacuna Pharma Pty Ltd
EGFR inhibitor-induced folliculitis
1 trial -
TCTLR-101
Lacuna Pharma Pty Ltd
Cancer
1 trial -
TEV-48574
Lacuna Pharma Pty Ltd
Crohn’s disease, Ulcerative colitis
1 trial -
TEV-53408, Placebo to match TEV-53408
Lacuna Pharma Pty Ltd
Celiac Disease
1 trial -
TG1-CL-301
Lacuna Pharma Pty Ltd
Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy
1 trial -
TL-895, TL-895
Lacuna Pharma Pty Ltd
B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
TL-895-201
Lacuna Pharma Pty Ltd
Indolent Systemic Mastocytosis
1 trial -
TMP-08012024-3
Lacuna Pharma Pty Ltd
Chronic spontaneous urticaria
1 trial -
TMP-18122023-58
Lacuna Pharma Pty Ltd
Adults with ADHD and moderate to severe depression
1 trial -
TOP-N53-02
Lacuna Pharma Pty Ltd
Digital ulcers in systemic sclerosis
1 trial -
TV48574-IMM-20036
Lacuna Pharma Pty Ltd
Crohn’s disease, Ulcerative colitis
1 trial -
Terbinafin "Moberg Pharma" for Distal Subungual Onychomycosis
Lacuna Pharma Pty Ltd
Distal Subungual Onychomycosis
1 trial -
Tovorafenib, Tovorafenib
Lacuna Pharma Pty Ltd
RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients
1 trial -
TransCon CNP, Placebo for TransCon CNP
Lacuna Pharma Pty Ltd
Achondroplasia in Children and Adolescents
1 trial -
UP-CLI-2023-01
Lacuna Pharma Pty Ltd
to obtain pre-operative mydriasis or for diagnostic purposes
1 trial -
VANCOMYCIN , MaaT013
Lacuna Pharma Pty Ltd
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
1 trial -
VDA-1102, VDA-1102 placebo
Lacuna Pharma Pty Ltd
Actinic keratosis
1 trial -
VP-C21-011
Lacuna Pharma Pty Ltd
idiopathic pulmonary fibrosis
1 trial -
VTX002-201
Lacuna Pharma Pty Ltd
Moderately to Severely Active Ulcerative Colitis
1 trial -
Vonafexor
Lacuna Pharma Pty Ltd
Alport Syndrome
1 trial -
WOE-DE-2023-2
Lacuna Pharma Pty Ltd
Diabetic sensorimotor polyneuropathy (DSPN)
1 trial -
ZADAXIN® 1,6 mg/ml
Lacuna Pharma Pty Ltd
Cystic Fibrosis
1 trial -
alpha 1H, Placebo product for Alpha1H
Lacuna Pharma Pty Ltd
Non-muscle invasive bladder cancer awaiting transurethral surgery
1 trial -
bimekizumab
Lacuna Pharma Pty Ltd
Moderate to Severe Plaque Psoriasis
1 trial -
non-preserved sterile liquid formulation
Lacuna Pharma Pty Ltd
Type 2 diabetes and Obesity
1 trial -
phosphate buffered saline., FX06
Lacuna Pharma Pty Ltd
Acute Respiratory Distress Syndrome (ARDS)
1 trial -
sotatercept, PL1 - Powder for injection
Lacuna Pharma Pty Ltd
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
1 trial -
ENV-202
Lacuna Pharma Pty Ltd
Fragile X Syndrome
1 trial
Frequently asked questions
How many clinical projects does Anaxis Pharma have?
223 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.